In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Manchester Pharmaceuticals LLC

Division of Retrophin Inc.
www.manchesterpharma.com

Latest From Manchester Pharmaceuticals LLC

Retrophin’s New Strategy Gets A Boost, And A Voucher, Thanks To Cholbam

The rare disease company, in the midst of a transition after losing its high-profile CEO last year, takes a step forward with the FDA approval of Cholbam for bile acid synthesis disorders. The company also gained a valuable priority review voucher, which it could sell.

BioPharmaceutical Strategy

Start-Up Quarterly Statistics, Q1 2014

Start-up companies raised $1.18 billion during the first quarter of 2014, up $2.8 million from last quarter’s total. Cancer was the leading therapy area involved in alliances.

BioPharmaceutical Medical Device

Deals Shaping The Medical Industry, March 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January through February 2014.

BioPharmaceutical Medical Device

Deals Of The Week: UCSF Catalyzes R&D Tech-Transfer Deals With Private Sector

Through the Catalyst Awards program at its Clinical and Translational Science Institute, UCSF will give MedImmune access to a broad range of discovery and preclinical opportunities under a three-year agreement. Plus, Mallinckrodt buys Cadence, Debiopharm acquires Affinium’s antibiotics program, and more.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Retrophin Inc.
  • Senior Management
  • Lloyd Glenn, Pres.
    Matthias Kurth, MD, PhD, VP, Medical & Regulatory Affairs
  • Contact Info
  • Manchester Pharmaceuticals LLC
    8236 Benson Ct.
    Fort Collins, CO 80525
    USA
UsernamePublicRestriction

Register